FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310127361> ?p ?o ?g. }

• W4310127361 endingPage "7746" @default.
• W4310127361 startingPage "7744" @default.
• W4310127361 abstract "Introduction For patients with high-risk acute leukemia (AL) lacking a matched sibling donor (MSD) or matched unrelated donor (MUD), an allogeneic stem cell transplant (alloSCT) from a haploidentical (HAPLO) donor is an increasingly used alternative. However, available data on the treatment of relapse after HAPLO-SCT is scarce. After a first transplant from MSD/MUD, a second allogeneic SCT (alloSCT2) using either MSD or MUD achieved 2-year overall survival (OS) in 20-30% of patients, independently of donor type for alloSCT2 and donor change. In contrast, there is little information supporting the feasibility and efficacy of a second HAPLO-SCT (HAPLO-SCT2) in patients with AL transplanted from a HAPLO donor at alloSCT1. On behalf of the Acute Leukaemia Working Party (ALWP) of the European Society of Blood and Marrow Transplantation (EBMT), we report here on the outcome of 82 patients with AL that underwent HAPLO-SCT2 after relapse from a first HAPLO- SCT in Europe. Methods This was a registry-based analysis of adults with acute myeloid leukemia and acute lymphoblastic leukemia (AML/ALL). All consecutive patients that had received a HAPLO-SCT2 without ex-vivo manipulation after hematologic relapse from HAPLO-SCT1 between 2007 and 2021 were included. Outcomes of interest were engraftment, OS, leukemia-free survival (LFS), non-relapse mortality (NRM), relapse incidence (RI), graft-versus-host disease (GvHD), and GvHD-free, relapse-free survival (GFRS) rates after HAPLO-SCT2. Results Eighty-two patients (AML, n=63, 77%; ALL, n=19, 23%) were identified. The median age at HAPLO-SCT2 was 47.2 years (range, 18.3-69.3) for AML and 33.5 (range, 19.7-58.2) for ALL (p=0.002), median interval from HAPLO-SCT1 to relapse was 7.5 months. A donor change between HAPLO-SCT1 and 2 was chosen in 35 (62.5%) of AML and 17 (89.5%) of ALL patients (p=0.042). Cell source was peripheral blood/bone marrow (PB/BM) in 15/67 (18%/82%), respectively. At HAPLO-SCT2, 21 (33.3%) AML patients had a complete remission (CR) and 49 (59.8%) an active disease, whereas 12 (63.2%) ALL patients were in CR (p=0.02). Reduced intensity conditioning (RIC) was used for HAPLO-SCT2 in 57% of patients, and post-transplant cyclophosphamide (PTCy) was the most frequent GvHD prophylaxis (82%). Following HAPLO-SCT2, median follow-up was 38/19 months for AML/ALL patients, respectively. In the entire cohort, 87% of patients engrafted. Cumulative incidences (CI) at day 180 of acute GvHD grade 2-4 and 3-4 were 23.9% and 15.3%, respectively. The CI of chronic GvHD and extensive chronic GvHD at 2 years was 22.6% and 11.2%, respectively. Overall, 2-year OS and LFS from HAPLO-SCT2 were 34.3% and 25.4%; 2-year NRM, RI, and GRFS rates were 17.6%, 57% 15.1%, respectively (Figure 1). When analysed separately by diagnose, 2-year OS/LFS were 28.7%/22.3% for AML and 55.3%/38.4% for ALL, respectively. NRM was relatively low (16.2%/23.5% in AML/ALL), while RI was considerable, reaching 61.6%/38.2% for AML/ALL, respectively. Consequently, leukemia was the most frequent cause of death. Among the 63 patients with AML, an analysis of risk factors for OS/LFS from HAPLO-SCT2 identified disease status at HAPLO-SCT1 (p=0.008/p=0.026), and at Haplo-SCT2 (p=0.047/p=0.043) as well as the interval from HAPLO-SCT1 to relapse (p=0.001/p=0.001) as most important variables. In contrast, conditioning intensity and change of donor did not make a significant difference. No clear risk factor was identified for NRM. Conclusion This is the largest cohort of patients undergoing double HAPLO-SCT analysed so far. Within the limits of a registry-based analysis, the data show the feasibility of a second HAPLO-SCT after relapse from HAPLO-SCT1 with high engraftment rates and acceptable NRM. Outcome data as well as risk factors are comparable to results reported after alloSCT2 in a matched donor setting. Results were encouraging among patients with ALL (n=19, only 2 with Philadelphia chromosome positive [Ph+] disease), who were younger and more often received HAPLO-SCT2 in CR and from a new donor. HAPLO-SCT2 is a viable option for AL patients relapsing after a HAPLO-SCT1. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
• W4310127361 created "2022-11-30" @default.
• W4310127361 creator A5008084507 @default.
• W4310127361 creator A5011772396 @default.
• W4310127361 creator A5019072713 @default.
• W4310127361 creator A5026667594 @default.
• W4310127361 creator A5027516224 @default.
• W4310127361 creator A5032172446 @default.
• W4310127361 creator A5034694882 @default.
• W4310127361 creator A5039007673 @default.
• W4310127361 creator A5040417184 @default.
• W4310127361 creator A5042277356 @default.
• W4310127361 creator A5042722243 @default.
• W4310127361 creator A5058925624 @default.
• W4310127361 creator A5068687462 @default.
• W4310127361 creator A5069596141 @default.
• W4310127361 date "2022-11-15" @default.
• W4310127361 modified "2023-10-18" @default.
• W4310127361 title "A Second Haploidentical Stem Cell Transplantation (HAPLO-SCT2) after Relapse from First Haplo-SCT Is Feasible and Produces Results That Are Comparable to Data Reported after Second SCT in an HLA-Matched Setting - a Study on Behalf of the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)" @default.
• W4310127361 doi "https://doi.org/10.1182/blood-2022-160229" @default.
• W4310127361 hasPublicationYear "2022" @default.
• W4310127361 type Work @default.
• W4310127361 citedByCount "0" @default.
• W4310127361 crossrefType "journal-article" @default.
• W4310127361 hasAuthorship W4310127361A5008084507 @default.
• W4310127361 hasAuthorship W4310127361A5011772396 @default.
• W4310127361 hasAuthorship W4310127361A5019072713 @default.
• W4310127361 hasAuthorship W4310127361A5026667594 @default.
• W4310127361 hasAuthorship W4310127361A5027516224 @default.
• W4310127361 hasAuthorship W4310127361A5032172446 @default.
• W4310127361 hasAuthorship W4310127361A5034694882 @default.
• W4310127361 hasAuthorship W4310127361A5039007673 @default.
• W4310127361 hasAuthorship W4310127361A5040417184 @default.
• W4310127361 hasAuthorship W4310127361A5042277356 @default.
• W4310127361 hasAuthorship W4310127361A5042722243 @default.
• W4310127361 hasAuthorship W4310127361A5058925624 @default.
• W4310127361 hasAuthorship W4310127361A5068687462 @default.
• W4310127361 hasAuthorship W4310127361A5069596141 @default.
• W4310127361 hasConcept C126322002 @default.
• W4310127361 hasConcept C143998085 @default.
• W4310127361 hasConcept C147483822 @default.
• W4310127361 hasConcept C188280979 @default.
• W4310127361 hasConcept C203014093 @default.
• W4310127361 hasConcept C2780303639 @default.
• W4310127361 hasConcept C28328180 @default.
• W4310127361 hasConcept C2909478873 @default.
• W4310127361 hasConcept C2911091166 @default.
• W4310127361 hasConcept C54355233 @default.
• W4310127361 hasConcept C71924100 @default.
• W4310127361 hasConcept C86803240 @default.
• W4310127361 hasConceptScore W4310127361C126322002 @default.
• W4310127361 hasConceptScore W4310127361C143998085 @default.
• W4310127361 hasConceptScore W4310127361C147483822 @default.
• W4310127361 hasConceptScore W4310127361C188280979 @default.
• W4310127361 hasConceptScore W4310127361C203014093 @default.
• W4310127361 hasConceptScore W4310127361C2780303639 @default.
• W4310127361 hasConceptScore W4310127361C28328180 @default.
• W4310127361 hasConceptScore W4310127361C2909478873 @default.
• W4310127361 hasConceptScore W4310127361C2911091166 @default.
• W4310127361 hasConceptScore W4310127361C54355233 @default.
• W4310127361 hasConceptScore W4310127361C71924100 @default.
• W4310127361 hasConceptScore W4310127361C86803240 @default.
• W4310127361 hasIssue "Supplement 1" @default.
• W4310127361 hasLocation W43101273611 @default.
• W4310127361 hasOpenAccess W4310127361 @default.
• W4310127361 hasPrimaryLocation W43101273611 @default.
• W4310127361 hasRelatedWork W1984578250 @default.
• W4310127361 hasRelatedWork W2027826350 @default.
• W4310127361 hasRelatedWork W2091768809 @default.
• W4310127361 hasRelatedWork W2127707359 @default.
• W4310127361 hasRelatedWork W2161710954 @default.
• W4310127361 hasRelatedWork W2185033940 @default.
• W4310127361 hasRelatedWork W2417656950 @default.
• W4310127361 hasRelatedWork W2422782754 @default.
• W4310127361 hasRelatedWork W2464208751 @default.
• W4310127361 hasRelatedWork W2524695531 @default.
• W4310127361 hasVolume "140" @default.
• W4310127361 isParatext "false" @default.
• W4310127361 isRetracted "false" @default.
• W4310127361 workType "article" @default.